Brought to you by 
Genzyme nets $11.2M in IPO spinoff 33% of Genzyme Transgenics
13 Jul 1999
Executive Summary
Genzyme has spun off 33% of its Genzyme Transgenics division (producing complex proteins in the milk of transgenic animals) in an initial public offering of 1.5 million common shares at $8 per share, raising net proceeds of $11.2 million.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Transgenics
Deal Status
- Final
Deal Type
-
Financing
- IPO
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme nets $11.2M in IPO spinoff 33% of Genzyme Transgenics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice